AzTrials
AzTrials

Intraocular Lens ComplicationNCT06974578

Capsular Tension Ring With Hydeophilic Intraocular Lesnes to Decrease Posterior Capsule Opacification Versus Hydrophobic Ones

A study testing phacoemulsification, CTR and hydrophilic IOL in people with Intraocular Lens Complication, run by Benha University at 1 site in Egypt.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

evaluate the clinical outcomes of routine CTR insertion in conjunction with hydrophilic versus hydrophobic IOLs following phacoemulsification. Read more about this study

Who is it for?
Ages 40 to 80 years
Conditions the study is for
Intraocular Lens Complication
What is being tested?
phacoemulsification, CTR and hydrophilic IOL
Could I receive a placebo?
No, everyone receives an active treatment
How many people
40 participants
Where
1 siteEgypt
Study dates
8 Feb 2024to 1 Sep 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 40 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • • Adults aged 40-80 years.
  • Visually significant cataract (≥3+ on Lens Opacities Classification System III "LOCSIII").
  • Clear cornea.

Who cannot join

  • • Previous ocular surgery.
  • Zonular instability requiring CTR insertion beyond routine practice.
  • Complicated cataract cases (e.g., traumatic cataract).
  • Active intraocular inflammation or infection.

Trial locations and contacts

1 site in 1 country.

Egypt1 site
  • Al-Azhar Faculty of Medicine

    Cairo

Other trials in Egypt

About this study

Official title: Assessment of the Outcomes of Routine Insertion of Capsular Tension Ring (CTR) With Hydrophilic Versus Hydrophobic Intraocular Lenses (IOLs) Alone After Phacoemulsification

evaluate the clinical outcomes of routine CTR insertion in conjunction with hydrophilic versus hydrophobic IOLs following phacoemulsification.

Read the detailed description

Phacoemulsification with intraocular lens (IOL) implantation is the standard surgical approach for cataract extraction. The choice between hydrophilic and hydrophobic IOLs has been debated, with studies suggesting differences in posterior capsule opacification (PCO) rates and capsular bag stability. Capsular tension rings (CTRs) are devices designed to stabilize the capsular bag, particularly in cases with zonular weakness. While CTRs are beneficial in complex cases, their routine use remains controversial. Understanding the interaction between CTRs and IOL materials could inform surgical practices and improve patient outcomes

Being tested
phacoemulsification, CTR, hydrophilic IOL, Hydrophobic IOL
Keywords
CTR, IOLs, Phacoemulsification

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • phacoemulsificationProcedure or surgery

    cataract extracton with phacoemulsification

  • CTRDevice

    insertion of capsualr tension ring

  • hydrophilic IOLDevice

    implantation of hydrophilic IOL

  • Hydrophobic IOLDevice

    insertion of hydrophobic IOL

Study groups in NCT06974578
Study groupRoleWhat they receive
Group A: CTR + Hydrophilic IOLActive comparatorphacoemulsification and insertion of CTR the hydrophilic IOL
Receives: Procedure: phacoemulsification; Device: CTR; Device: hydrophilic IOL
Group B: Hydrophobic IOL aloneActive comparatorphacoemulsification and insertiion of hydrophobic IOL
Receives: Procedure: phacoemulsification; Device: Hydrophobic IOL

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in BCVA (LogMAR)

    The formula: logMAR score (0.1 NL + 0.02 nl) where NL = number of lines completely read and nl = number of additional letters read ap- plies. For this method, the higher the logMAR VA score, the better the visual acuity.

    Measured: at 1, 3, and 6 months postoperatively.

  2. Refractive error measurements (spherical equivalent)

    SE was calculated as the spherical power of the refractive error plus one-half of the cylinder power. Hyperopia was defined as a spherical equivalent (SE) values of ≥ + 1.00 diopter (D) and emmetropia as a SE ranging between 0.99 and - 0.49 D. Myopia was defined as a SE refraction of ≤ -0.50 D.

    Measured: at 1, 3, and 6 months postoperatively.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted16 May 2025
  2. Study start8 Feb 2024
  3. Primary completion1 Sep 2024
  4. Study completion1 Sep 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
40 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06974578
Sponsor's protocol ID
CTR with IOL
Status last verified
May 2025
First submitted
8 May 2025
Last updated
16 May 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing phacoemulsification, CTR and hydrophilic IOL in people with Intraocular Lens Complication, run by Benha University at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 16 May 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in BCVA (LogMAR) (time frame: at 1, 3, and 6 months postoperatively.). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 May 2025; AzTrials last refreshed its copy on 27 Oct 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in